Evidence map›Paper›PMID 39901657›Full record

ArticleAngewandte Chemie (International ed. in English)2025

Amplified Production of a DNA Decoy Catalyzed by Intracellular MicroRNA.

Soshu Yasuda, Kunihiko Morihiro, Shuichiro Koga, Akimitsu Okamoto

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Amplified Production of a DNA Decoy Catalyzed by Intracellular MicroRNA.Angewandte Chemie (International ed. in English) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Soshu YasudaDepartment of Chemistry and Biotechnology, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, Japan.
Kunihiko MorihiroDepartment of Chemistry and Biotechnology, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, Japan.ORCID 0000-0002-9642-1031
Shuichiro KogaDepartment of Chemistry and Biotechnology, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, Japan.
Akimitsu OkamotoDepartment of Chemistry and Biotechnology, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, Japan.ORCID 0000-0002-7418-6237

Funding

Japan Agency for Medical Research and Development 23ak0101194h0001Japan Agency for Medical Research and Development JP22ym0126805j0001Japan Science and Technology Corporation JPMJAX191IJapan Society for the Promotion of Science 23H00317Japan Society for the Promotion of Science 23K17969
6 · The paper itself

Abstract

DNA decoys inhibit cellular transcription factors and are expected to be among the nucleic acid drugs used to downregulate the transcription process. However, spatially controlling the on/off efficacy of DNA decoys to avoid side effects on normal cells is challenging. To reduce undesired decoy function in normal cells, we adopted catalytic hairpin assembly (CHA) to produce a DNA duplex from a hairpin DNA pair in response to a specific microRNA (miRNA). We designed the DNA hairpin pairs to form a DNA decoy that binds to nuclear factor kappa B (NF-κB), whose overexpression is related to many diseases, including cancer. The transformation of the DNA hairpin pair to the NF-κB DNA decoy was catalyzed by miR-21, which is expressed in various types of cancers. Intracellular CHA progression and the inhibitory effect against NF-κB were observed only in miR-21 overexpressing cancer cells. The intracellular miR-21-catalyzed production of the NF-κB DNA decoy has the potential to reduce side effects on normal cells, thereby strengthening the therapeutic profile of the CHA-decoy system. The ability to customize the combination of catalytic miRNA and target transcription factors would allow our technology to serve as a "personalized drug discovery system" for a variety of challenging diseases, including cancer.

Indexed as

DNAMicroRNAsCatalysisCell Line, TumorHumansNF-kappa BOligodeoxyribonucleotidesDNAMicroRNAsMIRN21 microRNA, humanNF-kappa BNF-kappaB decoyOligodeoxyribonucleotidesCancerDNANanotechnologyNucleic acidsProdrugs

Identifiers

PMID39901657
PMCPMC11976199

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.